Close menu
Science Library Category:

25-Hydroxyvitamin D

Nutrients, Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.
Published: 2021
SYNOPSIS

Observational study showing improved immune system activity if supplementation was given to Vit D insufficient and deficient patients.

CITATION

Vassiliou AG, Jahaj E, Pratikaki M, Orfanos SE, Dimopoulou I, Kotanidou A. Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort. Nutrients. 2020 Dec 9;12(12):3773. doi: 10.3390/nu12123773. PMID: 33316914; PMCID: PMC7764169.

SUMMARY

We aimed to examine whether low intensive care unit (ICU) admission vitamin D levels are associated with worse outcomes of COVID-19 pneumonia. This was a prospective observational study of SARS-CoV2 positive critically ill patients treated in a multidisciplinary ICU. Thirty (30) Greek patients were included, in whom vitamin D level was measured on ICU admission. Eighty (80%) percent of patients had vitamin D deficiency, and the remaining insufficiency. All patients who died within 28 days belonged to the low vitamin D group. Survival analysis showed that the low vitamin D group had a higher 28-day survival absence probability. Critically ill COVID-19 patients who died in the ICU within 28 days appeared to have lower ICU admission vitamin D levels compared to survivors. It seems plausible, therefore, that low vitamin D levels may predispose COVID-19 patients to an increased 28-day mortality risk.

View Abstract

Nutrients, High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study.
Published: 2021
SYNOPSIS

An 80% decrease in death among hospitalized (late treatment) patients in the UK given Vitamin D.

CITATION

Ling SF, Broad E, Murphy R, Pappachan JM, Pardesi-Newton S, Kong MF, Jude EB. High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study. Nutrients. 2020 Dec 11;12(12):3799. doi: 10.3390/nu12123799. PMID: 33322317; PMCID: PMC7763301.

SUMMARY

This is a late treatment retrospective study showing 80% lower mortality with cholecalciferol booster therapy of 986 hospitalized patients in the UK finding that cholecalciferol booster therapy, regardless of baseline serum levels, was associated with a reduced risk of mortality in acute COVID-19 inpatients. An 80% decrease in mortality in the primary cohort (444 patients).

View Abstract